Fibrosis and Fibrotic Gene Expression in Pediatric and Adult Patients With Idiopathic Dilated Cardiomyopathy

Journal of Cardiac Failure

Volumn 23, Issue 4, 2017, Pages 314-324

  Woulfe, Kathleen C ^a   Siomos, Austine K ^b   Nguyen, Hieu ^b   SooHoo, Megan ^b   Galambos, Csaba ^b   Stauffer, Brian L ^a,c   Sucharov, Carmen ^a   Miyamoto, Shelley ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL COLORADO   (United States)

^c DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

Author keywords

fibrosis; gene expression; Pediatric idiopathic cardiomyopathy

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1A; CORIN PROTEIN; GALECTIN 3; GELATINASE A; GELATINASE B; INTERLEUKIN 1 RECEPTOR LIKE 1 PROTEIN; MICRORNA; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UNCLASSIFIED DRUG; INTERLEUKIN 1; MIRN29 MICRORNA, HUMAN; TISSUE INHIBITOR OF METALLOPROTEINASE;

ADULT; ARTICLE; CHILD; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DOWN REGULATION; ENDOCARDIAL FIBROSIS; FEMALE; FIBROSING ALVEOLITIS; GENE EXPRESSION; HEART LEFT VENTRICLE; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; AGE; CARDIAC MUSCLE; COMPLICATION; FIBROSIS; GENE EXPRESSION PROFILING; GENETICS; HEART FAILURE; HEART VENTRICLE; METABOLISM; MIDDLE AGED; PATHOLOGY; SIGNAL TRANSDUCTION; STATISTICS;

AGE FACTORS; CARDIOMYOPATHY, DILATED; CHILD; FEMALE; FIBROSIS; GALECTIN 3; GENE EXPRESSION PROFILING; HEART FAILURE; HEART VENTRICLES; HUMANS; INTERLEUKIN-1; MALE; MATRIX METALLOPROTEINASE 2; MICRORNAS; MIDDLE AGED; MYOCARDIUM; SIGNAL TRANSDUCTION; STATISTICS AS TOPIC; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 85009343165     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2016.11.006     Document Type: Article

References (53)

1. 1 Kirk, R., Edwards, L.B., Kucheryavaya, A.Y., Aurora, P., Christie, J.D., Dobbels, F., et al. The Registry of the International Society for Heart and Lung Transplantation: thirteenth official pediatric heart transplantation report—2010. J Heart Lung Transplant 29 (2010), 1119–1128.
2. 2 Towbin, J.A., Lowe, A.M., Colan, S.D., Sleeper, L.A., Orav, E.J., Clunie, S., et al. Incidence, causes, and outcomes of dilated cardiomyopathy in children. JAMA 296 (2006), 1867–1876.
3. 3 Kantor, P.F., Abraham, J.R., Dipchand, A.I., Benson, L.N., Redington, A.N., The impact of changing medical therapy on transplantation-free survival in pediatric dilated cardiomyopathy. J Am Coll Cardiol 55 (2010), 1377–1384.
4. 4 Rossano, J.W., Shaddy, R.E., Heart failure in children: etiology and treatment. J Pediatr 165 (2014), 228–233.
5. 5 Miyamoto, S.D., Stauffer, B.L., Nakano, S., Sobus, R., Nunley, K., Nelson, P., et al. Beta-adrenergic adaptation in paediatric idiopathic dilated cardiomyopathy. Eur Heart J 35 (2014), 33–41.
6. 6 Miyamoto, S.D., Karimpour-Fard, A., Peterson, V., Auerbach, S.R., Stenmark, K.R., Stauffer, B.L., et al. Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathy. J Heart Lung Transplant 34 (2015), 724–733.
7. 7 Nakano, S.J., Miyamoto, S.D., Movsesian, M., Nelson, P., Stauffer, B.L., Sucharov, C.C., Age-related differences in phosphodiesterase activity and effects of chronic phosphodiesterase inhibition in idiopathic dilated cardiomyopathy. Circ Heart Fail 8 (2014), 57–63.
8. 8 Gulati, A., Jabbour, A., Ismail, T.F., Guha, K., Khwaja, J., Raza, S., et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. JAMA 309 (2013), 896–908.
9. 9 Wu, K.C., Weiss, R.G., Thiemann, D.R., Kitagawa, K., Schmidt, A., Dalal, D., et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 51 (2008), 2414–2421.
10. 10 Assomull, R.G., Prasad, S.K., Lyne, J., Smith, G., Burman, E.D., Khan, M., et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 48 (2006), 1977–1985.
11. 11 Lehrke, S., Lossnitzer, D., Schob, M., Steen, H., Merten, C., Kemmling, H., et al. Use of cardiovascular magnetic resonance for risk stratification in chronic heart failure: prognostic value of late gadolinium enhancement in patients with non-ischaemic dilated cardiomyopathy. Heart 97 (2011), 727–732.
12. 12 Unverferth, D.V., Baker, P.B., Swift, S.E., Chaffee, R., Fetters, J.K., Uretsky, B.F., et al. Extent of myocardial fibrosis and cellular hypertrophy in dilated cardiomyopathy. Am J Cardiol 57 (1986), 816–820.
13. 13 Brilla, C.G., Maisch, B., Weber, K.T., Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation. Clin Investig 71:5 Suppl (1993), S35–41.
14. 14 Weber, K.T., Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13 (1989), 1637–1652.
15. 15 Ferrans, V.J., Pathologic anatomy of the dilated cardiomyopathies. Am J Cardiol 64 (1989), 9C–11C.
16. 16 de Leeuw, N., Ruiter, D.J., Balk, A.H., de Jonge, N., Melchers, W.J., Galama, J.M., Histopathologic findings in explanted heart tissue from patients with end-stage idiopathic dilated cardiomyopathy. Transpl Int 14 (2001), 299–306.
17. 17 Berk, B.C., Fujiwara, K., Lehoux, S., ECM remodeling in hypertensive heart disease. J Clin Invest 117 (2007), 568–575.
18. 18 Latus, H., Gummel, K., Klingel, K., Moysich, A., Khalil, M., Mazhari, N., et al. Focal myocardial fibrosis assessed by late gadolinium enhancement cardiovascular magnetic resonance in children and adolescents with dilated cardiomyopathy. J Cardiovasc Magn Reson, 17, 2015, 34.
19. 19 Zhang, Y., He, L., Cai, J., Lv, T., Yi, Q., Xu, Y., et al. Measurements in pediatric patients with cardiomyopathies: comparison of cardiac magnetic resonance imaging and echocardiography. Cardiology 131 (2015), 245–250.
20. 20 Etesami, M., Gilkeson, R.C., Rajiah, P., Utility of late gadolinium enhancement in pediatric cardiac MRI. Pediatr Radiol 46 (2015), 1096–1113.
21. 21 Burns, K.M., Byrne, B.J., Gelb, B.D., Kuhn, B., Leinwand, L.A., Mital, S., et al. New mechanistic and therapeutic targets for pediatric heart failure: report from a National Heart, Lung, and Blood Institute working group. Circulation 130 (2014), 79–86.
22. 22 Frunza, O., Russo, I., Saxena, A., Shinde, A.V., Humeres, C., Hanif, W., et al. Myocardial galectin-3 expression is associated with remodeling of the pressure-overloaded heart and may delay the hypertrophic response without affecting survival, dysfunction, and cardiac fibrosis. Am J Pathol 186 (2016), 1114–1127.
23. 23 French, B., Wang, L., Ky, B., Brandimarto, J., Basuray, A., Fang, J.C., et al. Prognostic value of galectin-3 for adverse outcomes in chronic heart failure. J Card Fail 22 (2016), 256–262.
24. 24 Dong, N., Chen, S., Wang, W., Zhou, Y., Wu, Q., Corin in clinical laboratory diagnostics. Clin Chim Acta 413 (2012), 378–383.
25. 25 Lee, R., Xu, B., Rame, J.E., Felkin, L.E., Barton, P., Dries, D.L., Regulated inositol-requiring protein 1–dependent decay as a mechanism of corin RNA and protein deficiency in advanced human systolic heart failure. J Am Heart Assoc, 3, 2014, e001104.
26. 26 Januzzi, J.L. Jr, ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res 6 (2013), 493–500.
27. 27 Sanada, S., Hakuno, D., Higgins, L.J., Schreiter, E.R., McKenzie, A.N., Lee, R.T., IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117 (2007), 1538–1549.
28. 28 Cushing, L., Kuang, P.P., Qian, J., Shao, F., Wu, J., Little, F., et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am J Respir Cell Mol Biol 45 (2011), 287–294.
29. 29 van Rooij, E., Sutherland, L.B., Thatcher, J.E., DiMaio, J.M., Naseem, R.H., Marshall, W.S., et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105 (2008), 13027–13032.
30. 30 Schneider, C.A., Rasband, W.S., Eliceiri, K.W., NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9 (2012), 671–675.
31. 31 Sucharov, C.C., Sucharov, J., Karimpour-Fard, A., Nunley, K., Stauffer, B.L., Miyamoto, S.D., Micro-RNA expression in hypoplastic left heart syndrome. J Card Fail 21 (2015), 83–88.
32. 32 Ochieng, J., Furtak, V., Lukyanov, P., Extracellular functions of galectin-3. Glycoconj J 19 (2004), 527–535.
33. 33 Calvier, L., Miana, M., Reboul, P., Cachofeiro, V., Martinez-Martinez, E., de Boer, R.A., et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 33 (2013), 67–75.
34. 34 Yu, L., Ruifrok, W.P., Meissner, M., Bos, E.M., van Goor, H., Sanjabi, B., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 6 (2013), 107–117.
35. 35 Ichiki, T., Huntley, B.K., Burnett, J.C. Jr, BNP molecular forms and processing by the cardiac serine protease corin. Adv Clin Chem 61 (2013), 1–31.
36. 36 Polyakova, V., Hein, S., Kostin, S., Ziegelhoeffer, T., Schaper, J., Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. J Am Coll Cardiol 44 (2004), 1609–1618.
37. 37 Polyakova, V., Loeffler, I., Hein, S., Miyagawa, S., Piotrowska, I., Dammer, S., et al. Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles. Int J Cardiol 151 (2011), 18–33.
38. 38 Herpel, E., Pritsch, M., Koch, A., Dengler, T.J., Schirmacher, P., Schnabel, P.A., Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy. Histopathology 48 (2006), 736–747.
39. 39 Peterson, J.T., Li, H., Dillon, L., Bryant, J.W., Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 46 (2000), 307–315.
40. 40 Thomas, C.V., Coker, M.L., Zellner, J.L., Handy, J.R., Crumbley, A.J. 3rd, Spinale, F.G., Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97 (1998), 1708–1715.
41. 41 Cauwe, B., Opdenakker, G., Intracellular substrate cleavage: a novel dimension in the biochemistry, biology and pathology of matrix metalloproteinases. Crit Rev Biochem Mol Biol 45 (2010), 351–423.
42. 42 Wang, W., Schulze, C.J., Suarez-Pinzon, W.L., Dyck, J.R., Sawicki, G., Schulz, R., Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106 (2002), 1543–1549.
43. 43 DeCoux, A., Lindsey, M.L., Villarreal, F., Garcia, R.A., Schulz, R., Myocardial matrix metalloproteinase-2: inside out and upside down. J Mol Cell Cardiol 77 (2014), 64–72.
44. 44 Lin, H.B., Sharma, K., Bialy, D., Wawrzynska, M., Purves, R., Cayabyab, F.S., et al. Inhibition of MMP-2 expression affects metabolic enzyme expression levels: proteomic analysis of rat cardiomyocytes. J Proteomics 106 (2014), 74–85.
45. 45 Hopps, E., Caimi, G., Matrix metalloproteases as a pharmacological target in cardiovascular diseases. Eur Rev Med Pharmacol Sci 19 (2015), 2583–2589.
46. 46 Lai, K.B., Sanderson, J.E., Izzat, M.B., Yu, C.M., Micro-RNA and mRNA myocardial tissue expression in biopsy specimen from patients with heart failure. Int J Cardiol 199 (2015), 79–83.
47. 47 Dawson, K., Wakili, R., Ordog, B., Clauss, S., Chen, Y., Iwasaki, Y., et al. MicroRNA29: a mechanistic contributor and potential biomarker in atrial fibrillation. Circulation 127 (2013), 1466–1475 75e1–28.
48. 48 Blechman, I., Arad, M., Nussbaum, T., Goldenberg, I., Freimark, D., Predictors and outcome of sustained improvement in left ventricular function in dilated cardiomyopathy. Clin Cardiol 37 (2014), 687–692.
49. 49 Yamada, Y., Saito, S., Nishinaka, T., Yamazaki, K., Myocardial size and fibrosis changes during left ventricular assist device support. ASAIO J 58 (2012), 402–406.
50. 50 Skrbic, B., Engebretsen, K.V., Strand, M.E., Lunde, I.G., Herum, K.M., Marstein, H.S., et al. Lack of collagen VIII reduces fibrosis and promotes early mortality and cardiac dilatation in pressure overload in mice. Cardiovasc Res 106 (2015), 32–42.
51. 51 Borg, T.K., Rubin, K., Lundgren, E., Borg, K., Obrink, B., Recognition of extracellular matrix components by neonatal and adult cardiac myocytes. Dev Biol 104 (1984), 86–96.
52. 52 Ruiz-Villalba, A., Ziogas, A., Ehrbar, M., Perez-Pomares, J.M., Characterization of epicardial-derived cardiac interstitial cells: differentiation and mobilization of heart fibroblast progenitors. PLoS ONE, 8, 2013 e53694.
53. 53 Norris, R.A., Borg, T.K., Butcher, J.T., Baudino, T.A., Banerjee, I., Markwald, R.R., Neonatal and adult cardiovascular pathophysiological remodeling and repair: developmental role of periostin. Ann N Y Acad Sci 1123 (2008), 30–40.